PRIMARY ANTIBIOTIC RESISTANCE AND EFFECTIVENESS OF CLARITHROMYCIN VS METRONIDAZOLE BASED THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHILDREN

Authors

  • Nadia Salman Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan https://orcid.org/0000-0002-5443-6569
  • Nighat Haider Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan
  • Muqaddar Shah Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan
  • Rehmana Waris Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan
  • Maryum Naseer Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan
  • Ayesha Razzaq Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan
  • Jai Krishin Children Hospital, Pakistan Institute of Medical Sciences, Islamabad-Pakistan

DOI:

https://doi.org/10.55519/JAMC-03-11648%20

Keywords:

Keywords: Clarithromycin, Metronidazole, resistance rate, Helicobacter pylori

Abstract

Background: NASPGHAN guidelines recommend regional antibiotic susceptibility profiling for H. pylori eradication treatment. Profiling local antibiotic resistance patterns is mandatory for successful H. pylori eradication in children. The aim of our study was to determine primary resistance to Clarithromycin and Metronidazole, most commonly used in the eradication regimens in children presenting with symptomatic H. pylori infection. This study was conducted at Children Hospital PIMS Islamabad from June 2020 to August 2021. Methods: The children of either gender age 2–14 years having symptomatic H. pylori infection (hematemesis, chronic abdominal pain) underwent stool for H. pylori Antigen. Children requiring urgent diagnostic endoscopy underwent rapid urease tests.  Biopsies were taken from children having positive stool H.pylori Ag and rapid urease test for histological examination. The biopsy specimens were cultured and subsequently tested for antibiotic sensitivity. Results:  Out of 54 children having H. pylori infection 40/54 (74.074%) children had strains susceptible to antimicrobials and 14/54 (25.92%) were having resistance to antimicrobials. According to the pattern of antimicrobial sensitivity, they were further grouped into three (a) Clarithromycin and Metronidazole sensitive group (18/40, 45%) (b) Clarithromycin sensitive and Metronidazole resistant group (12/40, 30%) (c) Metronidazole sensitive group (10/40 25%). Conclusion: Clarithromycin and Metronidazole cannot be used as1stline treatment for H. pylori eradication in children and can only be used with known antimicrobial susceptibility.

References

Hassan MN, Arif A, Shahzad MS, Ibrahim M, Rahman HA, Razaq MA, et al. The global prevalence of Helicobacter pylori and its effect on human health-Pakistan. Pure ApplBiol2020;9(1):936–48.

Curado MP, de Oliveira MM, deAraújoFagundes M. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: a systematic review and meta-analysis. Cancer Epidemiol2019;60:141–8.

Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance, and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. Helicobacter2017;22(5):e12400.

Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT,et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report.Gut2017;66(1):6–30.

Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, CasswallT,et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents. J Pediatr Gastroenterol Nutr2017;64(4):991–1003.

Aguilera Matos I, Diaz Oliva SE, Escobedo AA, Villa Jiménez OM, VelazcoVillaurrutia YDC. Helicobacter pylori infection in children. BMJ Paediatr Open 2020;4(1):e000679.

Sabbagh P, Mohammadnia-Afrouzi M, JavanianM, Babazadeh A, KoppoluV, Krishna V,et al. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J ClinMicrobiol Infect Dis 2019;38(1):55–66.

Li L, Ke Y, Yu C, Li G, Yang N, Zhang J, et al.Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years. Helicobacter 2017;22(3):e12373.

Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic Resistance of Helicobacter pylori Strains Isolated FromPediatric Patients in Southwest China. Front Microbiol2021;11:621791.

Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study. PeerJ 2021;9:e11518.

da Silva FAF, de Brito BB, Santos MLC, Marques HS, Sampaio MM, da Silva JúniorRT, et al. Treatment of Helicobacter pylori infection in children: A systematic review. World J Meta-Anal 2020;8(4):292–308.

Liu, Ds., Wang, Yh., Zhu, Zh, Zhang SH, Zhu X, Wan JH,et al. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control 2019;8:192.

Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter 2017;22(4):e12383.

Lu HH, Lai FP, Lo HY, Sheu BS, Yang YJ. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades. Helicobacter 2019;24(5):e12633.

Okuda M, Lin Y, Kikuchi S. Helicobacter pylori infection in children and adolescents. AdvExpMedBiol2019;1149:107–20.

Jaka H, Mueller A, Kasang C. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019:19(1);447.

Additional Files

Published

2023-07-09

Issue

Vol. 35 No. 3 (2023): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2023 Nadia Salman, Nighat Haider, Muqaddar Shah, Rehmana Waris, Maryum Naseer, Ayesha Razzaq, Jai Krishin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.